Microbes in the tumor microenvironment: New Additions to break the Tumor Immunotherapy Dilemma
L Zhou, S Fan, W Zhang, D Wang, D Tang - Microbiological Research, 2024 - Elsevier
Immunotherapies currently used in clinical practice are unsatisfactory in terms of therapeutic
response and toxic side effects, and therefore new immunotherapies need to be explored …
response and toxic side effects, and therefore new immunotherapies need to be explored …
[HTML][HTML] Identifying important microbial biomarkers for the diagnosis of colon cancer using a random forest approach
L Cao, S Wei, Z Yin, F Chen, Y Ba, Q Weng, J Zhang… - Heliyon, 2024 - cell.com
Colon cancer is one of the most common cancers, with 30–50% of patients returning or
metastasizing within 5 years of treatment. Increasingly, researchers have highlighted the …
metastasizing within 5 years of treatment. Increasingly, researchers have highlighted the …
Adjuvant therapy for high-risk melanoma: An in-depth examination of the state of the field
I Eljilany, E Castellano, AA Tarhini - Cancers, 2023 - mdpi.com
Simple Summary Patients with stage IIB-IV melanoma who have had surgery are
recommended to receive systemic adjuvant therapy, intended to target the residual micro …
recommended to receive systemic adjuvant therapy, intended to target the residual micro …